UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000033295
Receipt No. R000037815
Scientific Title Effect of Bifidobacterium administration on fecal IgA in full-term infants: a randomized control pilot trial
Date of disclosure of the study information 2019/05/31
Last modified on 2019/07/08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Effect of Bifidobacterium administration on fecal IgA in full-term infants: a randomized control pilot trial
Acronym Fecal IgA in full-term infants who take Bifidobacterium trial
Scientific Title Effect of Bifidobacterium administration on fecal IgA in full-term infants: a randomized control pilot trial
Scientific Title:Acronym Fecal IgA in full-term infants who take Bifidobacterium trial
Region
Japan

Condition
Condition normal birth-weight and full-term infant
Classification by specialty
Child
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The aim of this pilot trial is to calculate the sample size of the future main study. For this porpous, means and standard deviations of fecal IgA of two groups of infants, who use infant formula with or without Bifidobaterium.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Fecal IgA level of infants
Key secondary outcomes The number of Bifidobacterium bifidum in infant feces
Frequency of eczema in the study infants

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Food
Interventions/Control_1 A group: The test formula is the infant formula containing heat-treated Bifidobacterim bifidum OLB6378
Interventions/Control_2 C group: The infant formula without Bifidobacterium bifidum OLB6378. It is indistinguishable from the test infantformula in appearance.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit
2 days-old >=
Gender Male and Female
Key inclusion criteria 1. normal birth-weight (2,500 g <= birth-weight < 4,000 g ) infant and his/her mother
2. full-term (37 weeks <= gestational age < 42 weeks) infant and his/her mother
3. Signed consent form to participate in the study was obtained from the infant's mother as the legal representative after full explanation of this study and its ethical considerations to persons in parental authority.
Key exclusion criteria 1. infant with severe infection and his/her mother
2. infant with severe congenital abnormality and his/her mother
3. infant who is considered unsuitable subjects by the attending physician and his/her mother
Target sample size 100

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Naoki Shimojo
Organization Chiba University
Division name Graduate School of Medicine
Zip code
Address 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, JAPAN
TEL 043-226-2144
Email shimojo@faculty.chiba-u.jp

Public contact
Name of contact person
1st name
Middle name
Last name Hiroki Takayama
Organization Soiken Inc.
Division name Clinical Study Support Division
Zip code
Address NBF Ogawamachi Building 4F, 1-3-1 Ogawamachi, Kanda, Chiyoda-ku, Tokyo
TEL 03-3295-1350
Homepage URL
Email takayama@soiken.com

Sponsor
Institute Graduate School of Medicine, Chiba University
Institute
Department

Funding Source
Organization Meiji Co. Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2019 Year 05 Month 31 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2018 Year 03 Month 07 Day
Date of IRB
2018 Year 03 Month 07 Day
Anticipated trial start date
2018 Year 03 Month 07 Day
Last follow-up date
2019 Year 07 Month 30 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2018 Year 07 Month 05 Day
Last modified on
2019 Year 07 Month 08 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037815

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.